Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Capital Expenditures (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Capital Expenditures for 11 consecutive years, with $28000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Capital Expenditures changed N/A year-over-year to $28000.0, compared with a TTM value of $28000.0 through Sep 2025, changed N/A, and an annual FY2022 reading of $285000.0, up 375.0% over the prior year.
  • Capital Expenditures was $28000.0 for Q1 2025 at Lisata Therapeutics, up from -$9000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $28000.0 in Q1 2025 and bottomed at -$9000.0 in Q2 2023.